222 related articles for article (PubMed ID: 37669145)
1. Guanidyl-Rich Poly(β Amino Ester)s for Universal Functional Cytosolic Protein Delivery and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas9 Ribonucleoprotein Based Gene Editing.
Wang X; Li Y; Wang X; Sandoval DM; He Z; A S; Sáez IL; Wang W
ACS Nano; 2023 Sep; 17(18):17799-17810. PubMed ID: 37669145
[TBL] [Abstract][Full Text] [Related]
2. Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application.
Sun B; Chen H; Gao X
J Control Release; 2021 Sep; 337():698-717. PubMed ID: 34364918
[TBL] [Abstract][Full Text] [Related]
3. Supramolecular Nanosubstrate-Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion.
Ban Q; Yang P; Chou SJ; Qiao L; Xia H; Xue J; Wang F; Xu X; Sun N; Zhang RY; Zhang C; Lee A; Liu W; Lin TY; Ko YL; Antovski P; Zhang X; Chiou SH; Lee CF; Hui W; Liu D; Jonas SJ; Weiss PS; Tseng HR
Small; 2021 Jul; 17(28):e2100546. PubMed ID: 34105245
[TBL] [Abstract][Full Text] [Related]
4. Cyclization-enhanced poly(β-amino ester)s vectors for efficient CRISPR gene editing therapy.
Wang X; Li Y; A S; Lyu J; Wang X; He Z; Lara-Sáez I; Li M; Wang W
J Control Release; 2024 Apr; 368():444-452. PubMed ID: 38401849
[TBL] [Abstract][Full Text] [Related]
5. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
7. Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption.
Ha JS; Lee JS; Jeong J; Kim H; Byun J; Kim SA; Lee HJ; Chung HS; Lee JB; Ahn DR
J Control Release; 2017 Mar; 250():27-35. PubMed ID: 28167287
[TBL] [Abstract][Full Text] [Related]
8. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
9. Delivery of CRISPR-Cas12a Ribonucleoprotein Complex for Genome Editing in an Embryogenic Citrus Cell Line.
Fang H; Culver JN; Niedz RP; Qi Y
Methods Mol Biol; 2023; 2653():153-171. PubMed ID: 36995625
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation.
Ma L; Jang L; Chen J; Song J; Yang D; Zhang J; Chen YE; Xu J
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31282887
[TBL] [Abstract][Full Text] [Related]
11. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
12. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
13. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
14. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells.
Lin Y; Wilk U; Pöhmerer J; Hörterer E; Höhn M; Luo X; Mai H; Wagner E; Lächelt U
Small; 2023 Jan; 19(2):e2205318. PubMed ID: 36399647
[TBL] [Abstract][Full Text] [Related]
15. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
[TBL] [Abstract][Full Text] [Related]
16. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].
Li X; Shi W; Geng LZ; Xu JP
Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 therapeutics: progress and prospects.
Li T; Yang Y; Qi H; Cui W; Zhang L; Fu X; He X; Liu M; Li PF; Yu T
Signal Transduct Target Ther; 2023 Jan; 8(1):36. PubMed ID: 36646687
[TBL] [Abstract][Full Text] [Related]
18. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
[TBL] [Abstract][Full Text] [Related]
20. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
